Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone

J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):272-8. doi: 10.1097/00002371-199511000-00008.


The purpose of this prospective study was to determine the incidence of thyroid dysfunction in cancer patients receiving immunotherapy with interleukin-2 (IL-2) alone, and to assess the relationship of hypothyroidism to clinical response. A cohort of 281 consecutive patients with metastatic melanoma or renal carcinoma were treated with IL-2 alone from July 1, 1989 until June 30, 1993. The majority (n = 216) received high-dose IL-2 and the remainder (n = 65) received low-dose therapy. Thyroid function was measured before, during, and after immunotherapy. Forty-one percent of initially euthyroid patients developed thyroid dysfunction after starting high-dose IL-2-alone therapy. The most common abnormality was hypothyroidism, occurring in 35% of patients, although moderate or severe hypothyroidism requiring thyroid hormone replacement occurred in 9% of patients. Hypothyroidism was related to duration of IL-2 therapy and was not associated with clinical response. Hyperthyroidism developed in 7% of previously euthyroid patients receiving high-dose IL-2. Overall, the incidence of thyroid dysfunction was similar in the high- and low-dose IL-2 regimens. In conclusion, thyroid dysfunction is a common sequela of IL-2 therapy. Thyroid function should be measured routinely in cancer patients receiving IL-2-based treatment. It is recommended that thyroid hormone replacement be given to patients with moderate or severe hypothyroidism.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Carcinoma, Renal Cell / physiopathology*
  • Carcinoma, Renal Cell / therapy
  • Female
  • Humans
  • Hyperthyroidism / chemically induced
  • Hypothyroidism / chemically induced
  • Immunotherapy, Active / adverse effects
  • Interleukin-2 / adverse effects
  • Interleukin-2 / therapeutic use*
  • Male
  • Melanoma / physiopathology*
  • Melanoma / secondary*
  • Melanoma / therapy
  • Middle Aged
  • Prospective Studies
  • Thyroid Gland / physiopathology*


  • Interleukin-2